Medical devices (neuromodulation/TMS)

The company shape

Neuromodulation medical devices span several therapy categories with distinct buyer sets and reimbursement environments. Transcranial magnetic stimulation (TMS) treats major depressive disorder, obsessive-compulsive disorder, and increasingly other psychiatric indications through non-invasive magnetic pulses delivered by outpatient TMS coils; leading players are Neuronetics (NeuroStar), Magstim, MagVenture, and Brainsway. Spinal cord stimulation (SCS) treats chronic pain through implanted pulse generators and leads; leading players are Medtronic, Abbott (formerly St. Jude), Boston Scientific, Nevro, and Saluda Medical. Deep brain stimulation (DBS) treats Parkinson's disease, essential tremor, dystonia, and epilepsy; players are Medtronic, Abbott, and Boston Scientific. Vagus nerve stimulation (VNS) treats treatment-resistant epilepsy and treatment-resistant depression; the lead player is LivaNova. Sacral neuromodulation treats urinary and fecal incontinence; players are Medtronic and Axonics. Emerging categories include peripheral nerve stimulation, closed-loop neuromodulation, and non-invasive brain stimulation devices.

Revenue bands

Revenue bands span three zones. Large diversified medical device companies (Medtronic, Abbott, Boston Scientific) run neuromodulation as a business unit inside a larger portfolio, contributing $1B to $3B of neuromodulation revenue each. Focused neuromodulation companies (Neuronetics, Nevro, Axonics, LivaNova) run $200M to $700M in revenue, competing directly against the diversified players in their specific therapy category. Startup neuromodulation companies run $1M to $50M in revenue with venture funding and clinical development pipelines that consume five to fifteen years and $100M to $500M before commercial launch.

Structure follows regulatory design. Implantable neuromodulation devices for on-label indications typically require PMA approval with pivotal clinical trials, five to ten years of development, and coordinated CMS coverage engagement. Non-invasive TMS devices for depression received FDA clearance in 2008 and expanded indications through de novo and 510(k) pathways since. Every new indication requires new clinical trial data and often new coding, coverage, and payment engagement. Companies with pipeline products in expanded indications operate on multi-year horizons and structure commercial and marketing motions accordingly.

Commercial structure by therapy

Commercial structure runs through psychiatric, neurological, urological, and pain management specialist customers depending on the therapy. TMS commercial motion runs through outpatient psychiatric practices, integrated psychiatric groups, and university medical centers with psychiatric departments; the physician purchases or leases a TMS device and operates it as an in-office procedure, billing insurance for each treatment session. SCS commercial motion runs through pain management physician practices, ambulatory surgery centers, and hospital-based pain programs; the surgeon implants the device in a two-stage procedure (trial then permanent implantation). DBS runs through movement disorder neurology programs coordinated with neurosurgery. VNS runs through epileptology and treatment-resistant depression psychiatric practices. Sacral neuromodulation runs through urology and colorectal surgery. Each commercial channel has different sales team structure, different clinical training requirements, and different marketing channels.

The economic model varies by therapy. TMS is a high-volume, in-office procedure with per-session Medicare payment of roughly $200 to $250 and commercial payment often higher; a psychiatric practice with a TMS device generates $150,000 to $500,000 annually in incremental practice revenue. SCS is a lower-volume, higher-revenue-per-case product with device revenue of $20,000 to $30,000 per implant. DBS is a low-volume, high-complexity procedure with device revenue and long-term programming that produces multi-year practice relationships. VNS is a low-volume treatment-resistant patient population with committed adopter physicians. Sacral neuromodulation is a growing category with expanding indications.

The buyer

The buyer set differs sharply by therapy category, and marketing that treats neuromodulation as a single category misses the specifics that drive each purchase. TMS buyers are psychiatrists in outpatient practice, integrated behavioral health groups, and university psychiatric departments. They evaluate the device on treatment outcome data for major depressive disorder (typically remission rates from the pivotal registration studies and real-world evidence), workflow and time-per-treatment, patient tolerability, insurance authorization support, and the total practice revenue impact. The individual psychiatrist or the practice medical director drives the buying decision in solo and small group settings; in integrated groups a medical director and a practice CFO or administrator jointly evaluate.

SCS buyers are interventional pain management physicians, some anesthesiology-trained and some physical medicine and rehabilitation-trained, working in outpatient practices, ambulatory surgery centers, or hospital-based pain programs. They evaluate the device on clinical outcome data (pain reduction, opioid reduction, functional improvement), device features (MRI conditionality, closed-loop feedback in Saluda's Evoke product, high-frequency options in Nevro's Senza system), and the trial-to-permanent conversion rate that affects practice economics. The physician typically drives the decision with hospital VAC and ASC administrative approval.

DBS buyers are movement disorder neurologists coordinated with functional neurosurgeons. The neurologist identifies candidates, the surgeon implants the device, and the neurologist provides long-term programming and management. The buying committee spans two departments and often a comprehensive movement disorders center. Selection depends on the operator's clinical experience with the platform, the programming interface, the electrode array design, and MRI conditionality.

VNS buyers are epileptologists (for the epilepsy indication) and psychiatrists specializing in treatment-resistant depression (for the depression indication). The clinical population is small and the commercial motion is heavily KOL-driven, with a defined set of high-volume centers driving most of the volume nationally.

Sacral neuromodulation buyers are urologists and colorectal surgeons in outpatient and hospital-based practice. The buying committee spans the physician and hospital VAC for implantable cases and the physician alone for office-based cases.

Reimbursement is a first-order buyer concern in every neuromodulation category. TMS requires prior authorization from most commercial payers with specific documentation of prior antidepressant trial failures; the authorization process is a substantial administrative burden for the practice, and vendors that support authorization workflow (documentation templates, benefits verification, prior authorization assistance) reduce practice friction measurably. SCS requires pre-authorization for the trial and permanent implantation, with commercial payer variability. DBS requires the same. Coverage restrictions and prior authorization requirements affect commercial adoption more than clinical benefit does in most categories.

Patient influence matters in neuromodulation more than in most medical device categories because patients often research treatments before asking their physician about them. Depression and pain patients who research TMS or SCS on their own may specifically request the treatment from their psychiatrist or pain physician, and physician office visits driven by patient inquiry account for a meaningful percentage of new starts. Direct-to-consumer marketing (television, digital, print) reaches this patient audience and produces measurable physician inquiry lift.

Discovery landscape

Neuromodulation discovery blends physician research surfaces and patient research surfaces, and each therapy category runs through different channels. Physician discovery for TMS runs through psychiatric society meetings (American Psychiatric Association, Clinical TMS Society), Psychiatric News, Medscape Psychiatry, Doximity, and podcast series specific to psychiatry (Psychcast, MDedge Psychiatry Podcast). Society guidelines from the APA and specialty consensus documents shape treatment protocols. Peer-reviewed publications in JAMA Psychiatry, American Journal of Psychiatry, and Neuropsychopharmacology drive KOL and clinical opinion.

Physician discovery for SCS runs through pain society meetings (American Society of Anesthesiologists, North American Neuromodulation Society, American Academy of Pain Medicine), Pain News Network, and specialty publications. NANS is the primary neuromodulation clinical congress, and vendor presence at NANS shapes clinical opinion measurably. Peer-reviewed publications in Pain, Neuromodulation, and Journal of Pain Research drive clinical evidence conversation.

Patient discovery runs through disease education websites (Anxiety and Depression Association of America, National Alliance on Mental Illness for depression; American Chronic Pain Association, U.S. Pain Foundation for chronic pain; Michael J. Fox Foundation for Parkinson's; Epilepsy Foundation for epilepsy), Google search for symptom and treatment queries, Reddit communities specific to each condition, and increasingly AI answer engines where patients research treatment options. Vendors that structure patient-facing content for both physician-search parity and patient-friendly explanation earn share in both audiences.

Direct-to-consumer marketing is meaningful in TMS and SCS specifically. Neuronetics has run national television advertising for NeuroStar TMS for major depressive disorder for over a decade, and DTC ads produce measurable patient inquiry lift at treating psychiatric practices. Nevro and Boston Scientific have run DTC campaigns for SCS with similar effect. DTC is heavily regulated by the FDA under the 21 CFR 202 promotional guidance and requires balanced benefit and risk information, adequate provision, and specific brand-name mentions with fair balance.

AI answer engines are early but growing for both physician and patient neuromodulation research. Patients increasingly ask Perplexity, ChatGPT, and Claude about treatment options for depression, chronic pain, Parkinson's, and epilepsy, and the answer sets increasingly include or exclude neuromodulation depending on how the retrieval systems structure the content. Vendors that publish structured patient education and clinician education content earn AI citation share in a channel most neuromodulation manufacturers underweight.

Insurance authorization surfaces matter as discovery. Vendors that maintain payer coverage tracking, prior authorization support tools, and documentation templates for the treating clinician reduce the friction that limits adoption. This function sits closer to sales enablement than to discovery marketing, and the physician-facing tools produce word-of-mouth referral to the vendor across peer physician networks and constitute a real discovery surface in the practice manager audience.

What breaks most often

The first failure is treating neuromodulation as a single category in marketing. TMS marketing to psychiatrists differs from SCS marketing to pain physicians differs from DBS marketing to movement disorder neurologists. Vendors that publish generic "neuromodulation for chronic conditions" content miss the specifics that drive each purchase in each therapy area. Every product needs therapy-specific messaging, therapy-specific clinical evidence packages, and therapy-specific speaker rosters.

The second failure is under-investing in patient-facing marketing for the treatable indications. Patients research treatment options for depression, chronic pain, movement disorders, and treatment-resistant epilepsy before asking their physician. Vendors with strong patient-facing education content (symptom guides, treatment option comparisons, insurance navigation, patient testimonials with clear risk disclosure) produce measurable physician inquiry lift. Vendors without patient-facing content cede this channel to competitors.

The third failure is inadequate prior authorization support for the treating practice. TMS practices spend substantial administrative time on prior authorization for each new patient, and the burden limits adoption. Vendors that provide authorization workflow tools, documentation templates, benefits verification, and appeals support reduce practice friction and drive higher device utilization at existing customer practices. Vendors that treat prior authorization as the practice's problem miss a major adoption lever.

The fourth failure is FDA promotion violations in patient-facing DTC marketing. DTC promotional content for prescription medical devices requires fair balance between benefits and risks, adequate provision of full prescribing information, specific brand-name mention with the indication, and consistent messaging with the FDA-cleared or approved labeling. Marketing content that overstates efficacy, understates risk, or discusses off-label indications produces enforcement letters and warning actions that damage brand credibility. Every DTC asset needs an MLR review workflow with named regulatory affairs sign-off.

The fifth failure is weak clinical evidence pipeline post-launch. Post-approval clinical evidence generation drives the ongoing conversation with physicians and the eventual clinical guideline updates that expand the addressable market. Vendors that stop generating evidence after the pivotal registration study lose the clinical narrative to competitors publishing real-world evidence, longer-term follow-up, and expanded indication studies.

The sixth failure is missing the referring physician layer. In psychiatric TMS, the referring physician is often the primary care physician or the psychiatrist not currently offering TMS. In pain SCS, the referring physician is the general pain physician, primary care physician, or spine surgeon. In DBS, the referring physician is the general neurologist. Marketing that reaches only the treating physician misses the referral base that grows the practice's patient volume. Referring physician education content produces measurable patient referral lift to the treating practice.

The seventh failure is weak KOL program structure. Neuromodulation is heavily KOL-driven, and unstructured KOL programs fail to build the durable relationships that shape guidelines and society consensus. Structured KOL programs include tiered engagement (advisory board, speaker bureau, clinical proctor, investigator), Sunshine-compliant contracting, aggregate spend tracking, and quarterly relationship management. Companies with strong KOL programs shape society guidelines over multi-year horizons.

The Ranking Surfaces Playbook applied

Tier 1 for neuromodulation medical devices runs clinical evidence dissemination, E-E-A-T (physician and patient content with named credentialed authors), SEO (patient education queries and physician research queries), and patient-facing DTC where the indication supports it. Clinical evidence shapes physician selection in every neuromodulation therapy category. E-E-A-T requires named physician authors with subspecialty credentials for clinical content and clear medical review disclosures for patient content. SEO drives both patient inquiry to treating practices and physician research on new device data. DTC television and digital produces measurable patient inquiry for TMS and SCS specifically.

Tier 2 runs AEO, GEO, KGO, community, and prior authorization support. AEO and GEO citations reach both patient and physician research audiences with growing volume. KGO through Wikidata and Knowledge Panel matters for brand entity recognition. Community lives on Reddit (r/depression, r/ChronicPain, r/Parkinsons, r/Epilepsy) for patient discovery and on Medscape and specialty forums for physician discovery. Prior authorization support tools function as sales enablement content and also operate as a discovery surface in the practice manager audience.

Tier 3 runs CWV, VxSO, VSO, and podcast sponsorships. CWV signals engineering credibility. VxSO covers procedure images, patient outcome imagery (with consent), and device photography. VSO is an AEO free-rider. Pain, psychiatry, and neurology podcast sponsorships reach the practicing physician audience.

Tier 4 runs GLOBO, AAO, LSO, ASO, and Web3. GLOBO matters for vendors with EMEA and Asia-Pacific commercial footprints; each region has separate regulatory frameworks (EUDAMED for Europe, PMDA for Japan). AAO is not yet applicable. LSO applies for major regional office visibility. ASO applies for programming and companion apps. Web3 has no meaningful application.

First 30 / 60 / 90 days

Days 1 to 30: foundation and compliance

Days one through thirty focus on foundation and compliance. Audit every marketing asset against FDA on-label promotion limits with regulatory affairs sign-off, and rebuild any noncompliant DTC or physician-facing content. Audit the clinical evidence library and prioritize evidence gaps that limit expansion or coverage. Clean brand entity signals across Wikidata, sameAs, Organization schema, and society membership. Audit Sunshine Act reporting and confirm aggregate spend tracking. Audit the prior authorization support workflow and rebuild any broken elements (documentation templates, benefits verification, appeals support). Instrument Core Web Vitals on both physician-facing and patient-facing sites.

Days 31 to 60: content depth and KOL engagement

Days thirty through sixty focus on content depth and KOL and society engagement. Publish six long-form pieces on the therapy category with therapy-specific clinical evidence, direct-answer TL;DRs, FAQPage schema, and credentialed physician authorship. Publish six patient-facing education pieces with clear risk disclosure, medical review, and empathetic condition-specific voice for the treatable indication (depression, chronic pain, movement disorders, epilepsy). Ship the society engagement calendar for APA, NANS, ASA, AAN, and the specialty congresses. Open KOL relationships with three tier-one physicians per therapy area with Sunshine-compliant contracting. Launch chief medical officer and vice president of medical affairs LinkedIn presence with substantive clinical commentary. Publish two referring physician case studies to build the referral education content library.

Days 61 to 90: distribution and moat

Days sixty through ninety focus on distribution and moat. Ship AI answer engine structuring across all long-form clinical and patient content: TL;DR at 70 words, FAQ schema on the top three questions, HowTo schema on procedural or authorization content. Book speaker slots at the top three congresses and open industry-sponsored session proposals. Launch the DTC campaign for the treatable indication where the indication supports patient-facing marketing (TMS depression, SCS chronic pain), with full MLR review. Ship the prior authorization support content library with documentation templates for the top ten commercial payers by member count. Ship the medical education program with proctored cases and simulator training availability. Instrument attribution to track which surface each patient inquiry and each physician demo came from, split by treating practice and referring practice, and calibrate the ninety-day spend allocation against adoption and utilization metrics. By day ninety the device should have compliant DTC content, therapy-specific content pipelines, active KOL relationships, prior authorization support driving practice utilization, AI Overview citations for treatment education queries, and physician and patient discovery presence that reaches both audiences.